Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesBeta-Adrenergic Antagonists in Hypertension: A Review of the Evidence
Annals of Pharmacotherapy, 11/25/09
Warmack TS et al. – Overall, data supporting Beta–blockers as preferred therapy in hypertension are inadequate. Although most negative cardiovascular and cerebrovascular outcomes of beta–blockers were associated with atenolol therapy, data supporting other beta–blockers in hypertension are lacking.
Related Articles
Lessons in Hypertension from New Clinical Trials
Postgraduate Medicine, 11/24/09
Relevance Score: 94%
Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: Results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors
Journal of Clinical Oncology, 11/13/09
Relevance Score: 94%
Decrease in FASN Expression in Adipose Tissue of Hypertensive Individuals
American Journal of Hypertension, 11/23/09
Relevance Score: 92%
Practical strategies for management of hypertension in the elderly
Internet Source, 10/13/09
Relevance Score: 92%
Hypertension treatment and management concerns in the elderly
Aging Health, 10/07/09
Relevance Score: 92%
Today in Cardiac/Hypertension...keeping you current
Receive free subspecialty "5-minute updates" via email
Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population
Pharmacoepidemiology and Drug Safety, 02/09/10
Current Use of Aspirin and Antithrombotic Agents in the United States Among Outpatients With Atherothrombotic Disease
The American Journal of Cardiology, 02/08/10
Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension
Hypertension Research, 02/08/10
Article Search
Sponsor
Sponsor